EUVIMEDEUVIMED entdecken
FallberichtOpen Access

Long-term Disease Control After Probable Endobronchial Small-cell Transformation During Osimertinib Therapy for EGFR -mutant Lung Adenocarcinoma

Nozomu Murayama, Minehiko Inomata, Masahiro Matsumoto, Daisuke Furukawa, Tomomi Ichikawa, Yoshinobu Maeda, Hideki Shinno, Yuko Nakanishi, Shin Ishizawa

In Vivo · 2026-11 · 40 (6) · 3940-3946

DOI: 10.21873/invivo.14531 ↗

Kurz gefasst

Fallbericht in der Zeitschrift In Vivo, online erschienen am 29.10.2026. Verfasst von Nozomu Murayama und 8 weiteren Autor:innen. Beteiligte Einrichtung: First Department of Internal Medicine, Toyama University Hospital, Toyama, Japan; nozomum@med.u-toyama.ac.jp. Hauptthemen laut MEDLINE: Acrylamides, Adenocarcinoma of Lung, Aniline Compounds, Cell Transformation, Neoplastic. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcrylamidesAdenocarcinoma of LungAniline CompoundsCell Transformation, NeoplasticLung NeoplasmsMutationSmall Cell Lung CarcinomaHumansErbB ReceptorsIndolesPyrimidinesTomography, X-Ray ComputedTreatment OutcomeFemaleAged

Stichwörter der Autor:innen

EGFR-mutant lung adenocarcinomahistologic transformationmalignant central airway obstructionosimertinibsmall cell lung cancer

Substanzen

AcrylamidesAniline CompoundsEGFR protein, humanErbB ReceptorsIndolesosimertinibPyrimidines

Autor:innen und Institutionen

  • First Department of Internal Medicine, Toyama University Hospital, Toyama, Japan; nozomum@med.u-toyama.ac.jp.
  • First Department of Internal Medicine, Toyama University Hospital, Toyama, Japan.
  • Department of Respiratory and Allergy Medicine, Toyama Red Cross Hospital, Toyama, Japan.
  • Department of Diagnostic Pathology, Toyama Red Cross Hospital, Toyama, Japan.
  • Department of Thoracic Surgery, Toyama Prefectural Central Hospital, Toyama, Japan.
  • Department of Diagnostic Pathology, Toyama Prefectural Central Hospital, Toyama, Japan.

Zitieren

APA

Murayama, N., Inomata, M., Matsumoto, M., Furukawa, D., Ichikawa, T., Maeda, Y., Shinno, H., Nakanishi, Y., & Ishizawa, S. (2026). Long-term Disease Control After Probable Endobronchial Small-cell Transformation During Osimertinib Therapy for EGFR -mutant Lung Adenocarcinoma. In Vivo, 40(6), 3940-3946. https://doi.org/10.21873/invivo.14531

Vancouver

Murayama N, Inomata M, Matsumoto M, Furukawa D, Ichikawa T, Maeda Y, et al. Long-term Disease Control After Probable Endobronchial Small-cell Transformation During Osimertinib Therapy for EGFR -mutant Lung Adenocarcinoma. In Vivo. 2026;40(6):3940-3946. doi:10.21873/invivo.14531

BibTeX
@article{Murayama2026,
  author = {Murayama, Nozomu and Inomata, Minehiko and Matsumoto, Masahiro and Furukawa, Daisuke and Ichikawa, Tomomi and Maeda, Yoshinobu and Shinno, Hideki and Nakanishi, Yuko and Ishizawa, Shin},
  title = {Long-term Disease Control After Probable Endobronchial Small-cell Transformation During Osimertinib Therapy for EGFR -mutant Lung Adenocarcinoma},
  journal = {In Vivo},
  year = {2026},
  volume = {40},
  number = {6},
  pages = {3940--3946},
  doi = {10.21873/invivo.14531}
}
Kostenlos starten →